Cefazolin and Ertapenem Salvage Therapy Rapidly Clears Persistent Methicillin-Susceptible Staphylococcus Aureus Bacteremia

Overview

Journal Clin Infect Dis

Publisher Oxford University Press

Specialty Infectious Diseases

Date 2019 Nov 28

PMID 31773134

Citations 16

Authors

Erlinda R Ulloa

Kavindra V Singh

Matthew Geriak

Fadi Haddad

Barbara E Murray

Victor Nizet

George Sakoulas

Affiliations

Soon will be listed here.

Abstract

Cefazolin and ertapenem combination therapy was used successfully to salvage 11 cases (6 endocarditis) of persistent methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia, including immediate clearance (≤24 hours) in 8 cases. While in vitro synergy was modest, cefazolin plus ertapenem exhibited synergistic action in a rat model of MSSA endocarditis. The combination of cefazolin and ertapenem provides potent in vivo activity against MSSA beyond what is predicted in vitro and warrants further clinical study in the treatment of refractory MSSA bacteremia and endocarditis.

Citing Articles

Isolated Pulmonary Valve Infective Endocarditis With Persistent Staphylococcus aureus Bacteremia and Rapid Clearance With Ertapenem Plus Cefazolin.

Fernandes P, Maia Oliveira J, Rocha A, Carvalho S, Vaz J Cureus. 2025; 17(1):e77335.

PMID: 39935929 PMC: 11813253. DOI: 10.7759/cureus.77335.

Treatment of Complicated Gram-Positive Bacteremia and Infective Endocarditis.

Schellong P, Joean O, Pletz M, Hagel S, Weis S Drugs. 2024; 85(2):193-214.

PMID: 39720961 PMC: 11802659. DOI: 10.1007/s40265-024-02135-z.

Management of isolated native tricuspid valve infective endocarditis by a multidisciplinary program: a single-center retrospective cohort study.

Collis B, Alnabelsi T, Hall E, Cao C, Johnson M, Gurley J Ther Adv Infect Dis. 2024; 11:20499361241280690.

PMID: 39372129 PMC: 11452872. DOI: 10.1177/20499361241280690.

Acute drug-use-related native tricuspid valve infective endocarditis: a non-surgical disease.

El-Dalati S, Alnabelsi T, Gurley J, Cremeans K, Reda H, London-Bounds T Ther Adv Infect Dis. 2024; 11:20499361241267124.

PMID: 39132095 PMC: 11311191. DOI: 10.1177/20499361241267124.

Dual beta-lactam treatment: Pros and cons.

Guerra D, Vidal P, Paccoud O, Maillard A, Cachera L, Junot H Porto Biomed J. 2023; 7(5):e189.

PMID: 37213916 PMC: 10194505. DOI: 10.1097/j.pbj.0000000000000189.

References

Rincon S, Reyes J, Carvajal L, Rojas N, Cortes F, Panesso D . Cefazolin high-inoculum effect in methicillin-susceptible Staphylococcus aureus from South American hospitals. J Antimicrob Chemother. 2013; 68(12):2773-8. PMC: 3820105. DOI: 10.1093/jac/dkt254. View

Bryant R, ALFORD R . Unsuccessful treatment of staphylococcal endocarditis with cefazolin. JAMA. 1977; 237(6):569-70. View

QUINN E, Pohlod D, Madhavan T, Burch K, Fisher E, COX F . Clinical experiences with cefazolin and other cephalosporins in bacterial endocarditis. J Infect Dis. 1973; 128:Suppl:S386-9. DOI: 10.1093/infdis/128.supplement_2.s386. View

Doern C . When does 2 plus 2 equal 5? A review of antimicrobial synergy testing. J Clin Microbiol. 2014; 52(12):4124-8. PMC: 4313275. DOI: 10.1128/JCM.01121-14. View

Kumaraswamy M, Lin L, Olson J, Sun C, Nonejuie P, Corriden R . Standard susceptibility testing overlooks potent azithromycin activity and cationic peptide synergy against MDR Stenotrophomonas maltophilia. J Antimicrob Chemother. 2016; 71(5):1264-9. PMC: 4830416. DOI: 10.1093/jac/dkv487. View

Fernandez-Guerrero M, de Gorgolas M . Cefazolin therapy for Staphylococcus aureus bacteremia. Clin Infect Dis. 2005; 41(1):127. DOI: 10.1086/430833. View

Singh K, Tran T, Nannini E, Tam V, Arias C, Murray B . Efficacy of Ceftaroline against Methicillin-Susceptible Staphylococcus aureus Exhibiting the Cefazolin High-Inoculum Effect in a Rat Model of Endocarditis. Antimicrob Agents Chemother. 2017; 61(7). PMC: 5487651. DOI: 10.1128/AAC.00324-17. View

Weis S, Kesselmeier M, Davis J, Morris A, Lee S, Scherag A . Cefazolin versus anti-staphylococcal penicillins for the treatment of patients with Staphylococcus aureus bacteraemia. Clin Microbiol Infect. 2019; 25(7):818-827. DOI: 10.1016/j.cmi.2019.03.010. View

Pericas J, Cervera C, Rio A, Moreno A, Garcia de la Maria C, Almela M . Changes in the treatment of Enterococcus faecalis infective endocarditis in Spain in the last 15 years: from ampicillin plus gentamicin to ampicillin plus ceftriaxone. Clin Microbiol Infect. 2014; 20(12):O1075-83. DOI: 10.1111/1469-0691.12756. View

10.

Li J, Echevarria K, Hughes D, Cadena J, Bowling J, Lewis 2nd J . Comparison of cefazolin versus oxacillin for treatment of complicated bacteremia caused by methicillin-susceptible Staphylococcus aureus. Antimicrob Agents Chemother. 2014; 58(9):5117-24. PMC: 4135867. DOI: 10.1128/AAC.02800-14. View

11.

Sakoulas G, Olson J, Yim J, Singh N, Kumaraswamy M, Quach D . Cefazolin and Ertapenem, a Synergistic Combination Used To Clear Persistent Staphylococcus aureus Bacteremia. Antimicrob Agents Chemother. 2016; 60(11):6609-6618. PMC: 5075066. DOI: 10.1128/AAC.01192-16. View

12.

Chong Y, Park S, Kim E, Bang K, Kim M, Kim S . Prevalence of blaZ gene types and the cefazolin inoculum effect among methicillin-susceptible Staphylococcus aureus blood isolates and their association with multilocus sequence types and clinical outcome. Eur J Clin Microbiol Infect Dis. 2014; 34(2):349-55. DOI: 10.1007/s10096-014-2241-5. View

13.

Holland T, Arnold C, Fowler Jr V . Clinical management of Staphylococcus aureus bacteremia: a review. JAMA. 2014; 312(13):1330-41. PMC: 4263314. DOI: 10.1001/jama.2014.9743. View

14.

Fowler Jr V, Olsen M, Corey G, Woods C, Cabell C, Reller L . Clinical identifiers of complicated Staphylococcus aureus bacteremia. Arch Intern Med. 2003; 163(17):2066-72. DOI: 10.1001/archinte.163.17.2066. View

15.

Bamberger D, Herndon B, Fitch J, Florkowski A, Parkhurst V . Effects of neutrophils on cefazolin activity and penicillin-binding proteins in Staphylococcus aureus abscesses. Antimicrob Agents Chemother. 2002; 46(9):2878-84. PMC: 127421. DOI: 10.1128/AAC.46.9.2878-2884.2002. View

16.

Song K, Jung S, Lee S, Park S, Kim E, Park K . Inoculum effect of methicillin-susceptible Staphylococcus aureus against broad-spectrum beta-lactam antibiotics. Eur J Clin Microbiol Infect Dis. 2018; 38(1):67-74. DOI: 10.1007/s10096-018-3392-6. View

17.

Nannini E, Singh K, Arias C, Murray B . Effects of Cefazolin, Daptomycin, and Nafcillin in Experimental Endocarditis with a Methicillin-Susceptible Staphylococcus aureus Strain Showing an Inoculum Effect against Cefazolin. Antimicrob Agents Chemother. 2013; 57(9):4276-4281. PMC: 3754321. DOI: 10.1128/AAC.00856-13. View

18.

Nannini E, Singh K, Murray B . Relapse of type A beta-lactamase-producing Staphylococcus aureus native valve endocarditis during cefazolin therapy: revisiting the issue. Clin Infect Dis. 2003; 37(9):1194-8. DOI: 10.1086/379021. View

19.

Lin L, Nonejuie P, Munguia J, Hollands A, Olson J, Dam Q . Azithromycin Synergizes with Cationic Antimicrobial Peptides to Exert Bactericidal and Therapeutic Activity Against Highly Multidrug-Resistant Gram-Negative Bacterial Pathogens. EBioMedicine. 2015; 2(7):690-8. PMC: 4534682. DOI: 10.1016/j.ebiom.2015.05.021. View

20.

Nannini E, Stryjewski M, Singh K, Bourgogne A, Rude T, Corey G . Inoculum effect with cefazolin among clinical isolates of methicillin-susceptible Staphylococcus aureus: frequency and possible cause of cefazolin treatment failure. Antimicrob Agents Chemother. 2009; 53(8):3437-41. PMC: 2715590. DOI: 10.1128/AAC.00317-09. View